UGT2B17 affects bio‐active lipids, such as prostaglandin E2, through glucuronidation that impairs their anti‐oncogenic properties with subsequent effects on B‐cell proliferation, thereby contributing to disease progression in CLL patients overexpressing UGT2B17.23 The gene discussed is UGT2B17; the disease is B-cell chronic lymphocytic leukemia.